INRG Stage L2 Recruiting Phase 3 Trials for Dinutuximab (DB09077)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0113007 (INRG Stage L2) | Recruiting | 3 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT03126916 | Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma | Treatment |
|